|Other Names||Serine/threonine-protein kinase B-raf, Proto-oncogene B-Raf, p94, v-Raf murine sarcoma viral oncogene homolog B1, BRAF, BRAF1, RAFB1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP7810c was selected from the Center region of human BRAF. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Phosphorylates MAP2K1, and thereby contributes to the MAP kinase signal transduction pathway.|
|Cellular Location||Nucleus. Cytoplasm. Cell membrane. Note=Colocalizes with RGS14 and RAF1 in both the cytoplasm and membranes.|
|Tissue Location||Brain and testis.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
BRAF, a mebmer of the RAF subfamily of Ser/Thr protein kinases, is involved in the transduction of mitogenic signals from the cell membrane to the nucleus. It may play a role in the postsynaptic responses of hippocampal neuron. This cytoplasmic protein is expressed in brain and testis. Defects in BRAF are involved in a wide range of cancers including lung cancer and non-Hodgkin lymphoma (NHL). This protein contains 1 zinc-dependent phorbol-ester and DAG binding domain.
Loewe, R., et al., J. Invest. Dermatol. 123(4):733-736 (2004).Yamaguchi, T., et al., J. Biol. Chem. 279(39):40419-40430 (2004).Frattini, M., et al., Oncogene 23(44):7436-7440 (2004).Tsavachidou, D., et al., Cancer Res. 64(16):5556-5559 (2004).Gear, H., et al., Invest. Ophthalmol. Vis. Sci. 45(8):2484-2488 (2004).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.